Addex Therapeutics (ADXN) sells ADSs to extend cash runway

Rhea-AI Filing Summary

Addex Therapeutics Ltd. (ADXN) reported raising gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 American Depositary Shares (ADSs), representing 52,544,280 shares, under its At the Market (ATM) offering agreement with H.C. Wainwright & Co. Management states that, following this sale, the company’s cash runway is extended to the fourth quarter of 2027. The number of outstanding shares, excluding treasury shares, increased to 210,292,217 shares, while issued shares remained at 218,654,496 shares. The accompanying press release is incorporated by reference into Addex’s existing Form F-3 and Form S-8 registration statements.

Key Figures

Gross proceeds: USD 2.8 million Gross proceeds (CHF): CHF 2.2 million ADSs sold: 437,869 ADSs +3 more

6 metrics

Gross proceeds USD 2.8 million Raised through ATM sale of ADSs as announced on August 26, 2026

Gross proceeds (CHF) CHF 2.2 million Swiss franc equivalent of proceeds from ATM ADS sale

ADSs sold 437,869 ADSs Sold under At the Market (ATM) offering agreement with H.C. Wainwright & Co.

Shares represented by ADSs sold 52,544,280 shares Underlying shares represented by 437,869 ADSs sold

Outstanding shares 210,292,217 shares Outstanding shares excluding treasury shares after transaction

Issued shares 218,654,496 shares Total issued shares, unchanged after ATM transaction

Key Terms

At the Market (ATM) offering, American Depositary Shares, allosteric modulators, negative allosteric modulator, +1 more

5 terms

At the Market (ATM) offering financial

"through it’s At the Market (ATM) offering agreement with H.C. Wainwright & Co."

American Depositary Shares financial

"through the sale of 437,869 ADSs representing 52,544,280 shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

allosteric modulators medical

"developing a portfolio of novel small molecule allosteric modulators for neurological disorders"

Allosteric modulators are molecules that bind to a spot on a protein that is separate from the protein’s main active site and change how strongly the protein responds to its normal signals—like a dimmer switch that adjusts light instead of turning it fully on or off. For investors, they matter because this approach can yield drugs that are more selective, have fewer side effects, and offer novel patentable mechanisms, which can improve clinical success and commercial value.

negative allosteric modulator medical

"dipraglurant (mGlu5 negative allosteric modulator or NAM)"

A negative allosteric modulator is a drug or compound that binds to a site on a biological receptor different from where the body's natural molecule binds, and reduces the receptor's activity. Think of it as turning down the volume on a signal without cutting it off entirely. For investors, this mechanism can mean more selective effects, potentially fewer side effects, and distinct commercial and regulatory prospects compared with drugs that fully block or mimic a receptor.

IND enabling studies regulatory

"has selected a GABAB PAM drug candidate for development ... and has successfully completed IND enabling studies"

FAQ

How much capital did Addex Therapeutics (ADXN) raise in this 6-K update?

Addex Therapeutics raised USD 2.8 million (CHF 2.2 million) in gross proceeds through the sale of ADSs under its At the Market (ATM) offering agreement with H.C. Wainwright & Co., as disclosed in the report.

How many ADSs and underlying shares did Addex Therapeutics (ADXN) sell?

Addex Therapeutics sold 437,869 ADSs, which represent 52,544,280 shares of the company. These ADSs were issued pursuant to its At the Market (ATM) offering agreement.

What is Addex Therapeutics’ (ADXN) updated cash runway after this ATM transaction?

Addex Therapeutics states that, following the reported ATM sale, its cash runway has been extended to the fourth quarter of 2027, providing additional funding visibility for its operations and development programs.

What is the current outstanding and issued share count for Addex Therapeutics (ADXN)?

After the transaction, Addex reports 210,292,217 shares outstanding (excluding treasury shares), while issued shares remain at 218,654,496. The increase relates to shares underlying the ADSs sold in the ATM offering.

How is this 6-K incorporated into Addex Therapeutics’ (ADXN) SEC registration statements?

Exhibit 99.1 to this 6-K is deemed incorporated by reference into Addex’s Form F-3 (No. 333-291644) and Form S-8 (Nos. 333-255124 and 333-272515) registration statements, becoming part of those registration statements from the filing date.

What type of company is Addex Therapeutics (ADXN) and what is its lead program?

Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders. Its lead candidate, dipraglurant (mGlu5 negative allosteric modulator), is being evaluated for future development in brain injury recovery.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/26/2026 - 06:05 AM Accepted by SEC EDGAR 08/26/2026 - 06:05 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-39179

Addex Therapeutics Ltd
(Translation of registrant's name into English)

Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On August 26, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated August 26, 2026

INCORPORATION BY REFERENCE

Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-291644) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

RISK FACTORS

Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission on May 15, 2026. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described in our Annual Report and our other SEC filings.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Addex Therapeutics Ltd
		(Registrant)
Date: August 26, 2026		/s/ Tim Dyer
		Tim Dyer
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press release dated August 26, 2026

EXHIBIT 99.1

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it’s At the Market (ATM) offering agreement with H.C. Wainwright & Co.

Following the reported sale of these ADSs, Addex’s cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to 210,292,217 shares whilst the issued shares remained unchanged at 218,654,496 shares.

About Addex Therapeutics:

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex holds a 20% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.  

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com. 
  
Contacts: 

Tim Dyer 
Chief Executive Officer 
Telephone: +41 22 884 15 55 
PR@addextherapeutics.com  Mike Sinclair 
Partner, Halsin Partners 
+44 (0)7968 022075 
msinclair@halsin.com 

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.5 KB